Trials / Terminated
TerminatedNCT00414206
Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)
A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (NV-AMD)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 343 (actual)
- Sponsor
- CoMentis · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with neovascular ("wet") age-related macular degeneration (NV-AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mecamylamine | |
| DRUG | Placebo |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2009-06-01
- Completion
- 2009-09-01
- First posted
- 2006-12-21
- Last updated
- 2010-11-23
- Results posted
- 2010-11-23
Locations
42 sites across 6 countries: Brazil, Czechia, Mexico, Poland, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00414206. Inclusion in this directory is not an endorsement.